# Biopharma's Future Plant Infrastructure Challenge How manufacturers are redesigning facilities to handle complex drug portfolios - **Source:** [McKinsey Insights](https://www.mckinsey.com/insights) - **Published:** 2026-09-15 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/d6c10407-f54b-4d57-b9b2-9e403fd30e04 ## Growing complexity demands change Biopharmaceutical manufacturers face increasing challenges as drug portfolios become more specialized and complex. Traditional production facilities struggle to accommodate diverse molecule types and personalized therapies. This complexity reduces operational flexibility while increasing validation and changeover times between production runs. ## Productivity plateau pressures After years of steady efficiency gains, biopharma manufacturing productivity growth has slowed significantly. Equipment utilization rates have hit ceilings in many facilities, while yield improvements show diminishing returns. These constraints emerge just as demand for biologics and advanced therapies accelerates globally. ## Capacity expansion limitations While many manufacturers initially responded to demand growth by building new facilities, pure capacity additions prove insufficient. New plants often replicate outdated designs, perpetuating flexibility constraints. Construction lead times of 3-5 years also make rapid adaptation to new therapies impossible through building alone. ## Next-gen facility requirements Future biopharma plants require modular designs supporting multiple production technologies simultaneously. This includes flexible cleanroom configurations, single-use equipment integration, and advanced process automation. Digital twin capabilities will enable virtual testing of new production configurations before physical implementation. ## Network optimization strategies Leading manufacturers are shifting from standalone facilities to optimized production networks. This involves specializing sites by technology platform while maintaining flexible capacity buffers. Such networks allow rapid scaling of successful therapies while containing costs of failed candidates during clinical trials. ## Regulatory adaptation needs Current good manufacturing practice (cGMP) standards weren't designed for flexible, multi-product facilities. Regulators and manufacturers must collaborate to develop new validation approaches for modular systems. This includes real-time monitoring protocols and risk-based release testing frameworks. ## Talent infrastructure gap Next-gen facilities require operators skilled in both traditional bioprocessing and digital systems. The industry faces shortages of personnel capable of managing hybrid mechanical-digital environments. Upskilling programs must accelerate to match new facility commissioning timelines. ## Strategic investment imperative Biopharma companies must view manufacturing infrastructure as a competitive differentiator rather than a cost center. Future leaders will be those who successfully balance therapeutic innovation with production system adaptability. The transition requires capital discipline and long-term operational vision simultaneously. ## Sources covering this story - https://www.mckinsey.com/industries/life-sciences/our-insights/backbones-and-networks-a-blueprint-for-the-biopharma-plant-of-the-future — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._